stockrowAmylyx Pharmaceuticals, Inc.
AMLX Healthcare Drug Manufacturers Specialty & Generic
Amylyx Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $87.4 million, down 77.1% from fiscal 2023.
- Revenue
- −100.6%
- EPS
- +15.2%
- Free cash flow
- −24.5%
Quarter to June 2026, against a year earlier
Follow AMLX
Alert me
Amylyx Pharmaceuticals, Inc. (AMLX) Return on equity
Amylyx Pharmaceuticals, Inc.'s return on equity over the twelve months to 30 June 2026 was −74.7%, down 13.1 percentage points from fiscal 2025 (−61.6%). Over the past ten years it has ranged from −209.4% (fiscal 2022) to 80.7% (fiscal 2021); the current reading is higher than 50% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of −0.80% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −61.6% | 39.29 |
| FY2024 | −100.9% | (113.61) |
| FY2023 | 12.7% | 222.16 |
| FY2022 | −209.4% | (290.14) |
| FY2021 | 80.7% | 80.71 |
| FY2020 | 0.00% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| LQDA Liquidia Corporation compare | 131.8% |
| PBH Prestige Consumer Healthcare Inc. compare | 8.23% |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 0.00% |
| RGC Regencell Bioscience Holdings Limited compare | 0.00% |
| HIMS Hims & Hers Health, Inc. compare | −32.0% |
| TRLV Trulieve Cannabis Corp. compare | −45.5% |
| PRGO Perrigo Company plc compare | −51.4% |
| AMLX Amylyx Pharmaceuticals, Inc. | −74.7% |
| SUPN Indivior Pharmaceuticals Inc. compare | −337.8% |
| Drug Manufacturers Specialty & Generic industry median | −0.80% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on AMLX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement